Although numerous studies have reported the cardioprotective effect of Met, to our knowledge, this novel study is the first one to investigate the cardioprotective effect of Met against CH through the HIF-1α/PPAR-γ signaling pathway. The gene discussed is PPARG; the disease is cyclic hematopoiesis.